The Impact of CD19 Expression Combined with Measurable Residual Disease on Post-Remission Treatment and Outcome in Adult t(8;21) Acute Myeloid Leukemia

Background: Acute myeloid leukemia (AML) with t(8;21) has considerable clinical heterogeneity. Only 50% of these patients receiving multiple cycles of high-dose cytarabine as post-remission treatments could achieve long term survival, and relapse occures in up to 40% of them. Therefore, further risk stratification is needed to guide appropriate post-remission treatment for t(8;21) AML patitents in first complete remission(CR1). Measurable residual disease (MRD) monitored by RUNX1-RUNX1T1 transcript levels after treatment is established as a powerful marker to predict relapse and guide treatment. Recent studies revealed cell-surface antigen CD19 negativity (CD19-) was a risk factor for relapse in t(8;21) AML. However, reports about the impact of CD19 expression combined with RUNX1-RUNX1T1 MRD on post-remission treatment remains absent to date.